Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy by Templin, Christian et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2015
Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy
Templin, Christian; Ghadri, J R; Diekmann, J; Napp, L C; Seifert, Burkhardt; et al
Abstract: BACKGROUND The natural history, management, and outcome of takotsubo (stress) car-
diomyopathy are incompletely understood. METHODS The International Takotsubo Registry, a con-
sortium of 26 centers in Europe and the United States, was established to investigate clinical features,
prognostic predictors, and outcome of takotsubo cardiomyopathy. Patients were compared with age- and
sex-matched patients who had an acute coronary syndrome. RESULTS Of 1750 patients with takotsubo
cardiomyopathy, 89.8% were women (mean age, 66.8 years). Emotional triggers were not as common
as physical triggers (27.7% vs. 36.0%), and 28.5% of patients had no evident trigger. Among patients
with takotsubo cardiomyopathy, as compared with an acute coronary syndrome, rates of neurologic
or psychiatric disorders were higher (55.8% vs. 25.7%) and the mean left ventricular ejection fraction
was markedly lower (40.7±11.2% vs. 51.5±12.3%) (P<0.001 for both comparisons). Rates of severe
in-hospital complications including shock and death were similar in the two groups (P=0.93). Physical
triggers, acute neurologic or psychiatric diseases, high troponin levels, and a low ejection fraction on ad-
mission were independent predictors for in-hospital complications. During long-term follow-up, the rate
of major adverse cardiac and cerebrovascular events was 9.9% per patient-year, and the rate of death was
5.6% per patient-year. CONCLUSIONS Patients with takotsubo cardiomyopathy had a higher prevalence
of neurologic or psychiatric disorders than did those with an acute coronary syndrome. This condition
represents an acute heart failure syndrome with substantial morbidity and mortality. (Funded by the
Mach-Gaensslen Foundation and others; ClinicalTrials.gov number, NCT01947621.).
DOI: 10.1056/NEJMoa1406761
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-112874
Published Version
Originally published at:
Templin, Christian; Ghadri, J R; Diekmann, J; Napp, L C; Seifert, Burkhardt; et al (2015). Clinical
Features and Outcomes of Takotsubo (Stress) Cardiomyopathy. New England Journal of Medicine,
373(10):929-938. DOI: 10.1056/NEJMoa1406761
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 373;10 nejm.org September 3, 2015 929
The authors’ full names, academic degrees, 
and affiliations are listed in the Appendix. 
Address reprint requests to Dr. Templin 
at the University Hospital Zurich, Univer-
sity Heart Center, Department of Cardiol-
ogy, Rämistr. 100, 8091 Zurich, Switzer-
land, or at  christian . templin@ usz . ch.
Drs. Templin and Ghadri contributed 
equally to this article.
N Engl J Med 2015;373:929-38.
DOI: 10.1056/NEJMoa1406761
Copyright © 2015 Massachusetts Medical Society.
BACKGROUND
The natural history, management, and outcome of takotsubo (stress) cardiomyopa-
thy are incompletely understood.
METHODS
The International Takotsubo Registry, a consortium of 26 centers in Europe and 
the United States, was established to investigate clinical features, prognostic pre-
dictors, and outcome of takotsubo cardiomyopathy. Patients were compared with 
age- and sex-matched patients who had an acute coronary syndrome.
RESULTS
Of 1750 patients with takotsubo cardiomyopathy, 89.8% were women (mean age, 
66.8 years). Emotional triggers were not as common as physical triggers (27.7% 
vs. 36.0%), and 28.5% of patients had no evident trigger. Among patients with 
takotsubo cardiomyopathy, as compared with an acute coronary syndrome, rates 
of neurologic or psychiatric disorders were higher (55.8% vs. 25.7%) and the mean 
left ventricular ejection fraction was markedly lower (40.7±11.2% vs. 51.5±12.3%) 
(P<0.001 for both comparisons). Rates of severe in-hospital complications includ-
ing shock and death were similar in the two groups (P = 0.93). Physical triggers, 
acute neurologic or psychiatric diseases, high troponin levels, and a low ejection 
fraction on admission were independent predictors for in-hospital complications. 
During long-term follow-up, the rate of major adverse cardiac and cerebrovascular 
events was 9.9% per patient-year, and the rate of death was 5.6% per patient-year.
CONCLUSIONS
Patients with takotsubo cardiomyopathy had a higher prevalence of neurologic or 
psychiatric disorders than did those with an acute coronary syndrome. This condi-
tion represents an acute heart failure syndrome with substantial morbidity and 
mortality. (Funded by the Mach-Gaensslen Foundation and others; ClinicalTrials 
.gov number, NCT01947621.)
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Since its first description in Japan in 1990,1 takotsubo (stress) cardiomyopa-thy has gained worldwide recognition. 
However, after nearly 25 years of extensive ef-
forts toward a better understanding of this dis-
order, current knowledge remains limited. The 
disease is characterized by transient systolic and 
diastolic left ventricular dysfunction with a vari-
ety of wall-motion abnormalities.2,3 It predomi-
nantly affects elderly women and is often pre-
ceded by an emotional or physical trigger,4 but 
the condition has also been reported with no 
evident trigger. In the acute phase, the clinical 
presentation, electrocardiographic findings, and 
biomarker profiles are often similar to those of 
an acute coronary syndrome. Although the cause 
of takotsubo cardiomyopathy remains unknown, 
the role of the brain–heart axis in the pathogen-
esis of the disease has been described.5,6
Takotsubo cardiomyopathy, which derives its 
name from the Japanese word takotsubo (“octo-
pus pot”) to describe the characteristic balloon-
ing of the left ventricular apex, is generally rec-
ognized as a benign disorder. However, patients 
are at risk for recurrence even years after the 
first event, and data on in-hospital and long-
term outcomes are limited.7-10 The potential role 
of catecholamine excess in the pathogenesis of 
takotsubo cardiomyopathy has been long de-
bated,11 and as such beta-blockers have been pro-
posed as a therapeutic strategy.12 Nevertheless, 
to our knowledge, no prospective trials evaluating 
the therapeutic management have been reported 
to date. The aim of this study was to investigate 
the clinical features, define prognostic predic-
tors, and assess the clinical course and outcome 
of takotsubo cardiomyopathy.
Me thods
Study Population
The International Takotsubo Registry (www 
. takotsubo-registry . com) was established at Uni-
versity Hospital Zurich in collaboration with 25 
cardiovascular centers across 9 countries (Austria, 
Finland, France, Germany, Italy, Poland, Switzer-
land, the United Kingdom, and the United States) 
(see the Methods section in the Supplementary 
Appendix, available with the full text of this ar-
ticle at NEJM.org). Data were collected in accor-
dance with regulations set forth by institutional 
review boards. From 2011 through 2014, a core 
team of investigators at the University Hospital 
Zurich reviewed the records of patients in whom 
takotsubo cardiomyopathy had been diagnosed 
between 1998 and 2014 (Fig. 1). Patients were 
included in the registry on the basis of the Mayo 
Clinic diagnostic criteria for this condition,13 as 
follows: the presence of a transient abnormality 
in left ventricular wall motion beyond a single 
epicardial coronary artery perfusion territory, the 
absence of obstructive coronary artery disease or 
angiographic evidence of acute plaque rupture, 
the presence of new electrocardiographic abnor-
malities or elevation in cardiac troponin levels, 
and the absence of pheochromocytoma and myo-
carditis. Exceptions to these criteria were the 
presence of coexisting coronary artery disease, 
the presence of a wall-motion abnormality that 
was congruent with a single coronary artery ter-
ritory in a patient matching all other criteria, 
and death during the acute phase before wall-
motion recovery.
When eligibility for inclusion was uncertain, 
cases were reviewed by all members of the core 
team of investigators to reach consensus. Stan-
dardized forms were used to collect patient data, 
including baseline characteristics, triggering fac-
tors (categorized as emotional or physical) (Fig. S2 
in the Supplementary Appendix)9, cardiovascular 
risk factors, coexisting illnesses, results on elec-
trocardiography and echocardiography, laboratory 
values, results on coronary angiography, use of 
medications, and use of critical care. Takotsubo 
cardiomyopathy was classified as apical, mid-
ventricular, basal, or focal (see the Methods sec-
tion in the Supplementary Appendix).
Comparison of Takotsubo Cardiomyopathy 
and Acute Coronary Syndrome
We compared a subgroup of 455 patients in whom 
takotsubo cardiomyopathy had been diagnosed 
with 455 age- and sex-matched patients with an 
acute coronary syndrome who either fulfilled 
the third universal definition of myocardial 
infarction14 or had unstable angina caused by 
obstructive coronary artery disease. Data for 
patients with takotsubo cardiomyopathy were 
collected from five dedicated study centers (see 
the Methods section in the Supplementary Ap-
pendix), and data for patients with an acute coro-
nary syndrome were collected from the Zurich 
Acute Coronary Syndrome Registry, since these 
centers had the most comprehensive patient 
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records, including neurologic and psychiatric di-
agnoses according to the Diagnostic and Statistical 
Manual of Mental Disorders, fourth edition.15
Outcomes
We recorded all in-hospital complications, includ-
ing catecholamine use, cardiogenic shock, the 
use of invasive or noninvasive ventilation or 
cardiopulmonary resuscitation, and death from 
any cause. Follow-up analysis included death 
from any cause and major adverse cardiac and 
cerebrovascular events (a composite of a recur-
rence of takotsubo cardiomyopathy, myocardial 
infarction, stroke or transient ischemic attack, 
or death from any cause). Follow-up data ob-
tained by core team members were based on 
clinical visits, medical records, or telephone in-
terviews. In cases in which the native language 
of the patients did not allow for follow-up by 
core team members (e.g., in Finland and Italy), 
follow-up was obtained by local investigators on 
the basis of a dedicated case-report form. One-
year mortality was analyzed in subgroups of 
patients who were defined according to the use 
of angiotensin-converting–enzyme inhibitors, 
angiotensin-receptor blockers, or beta-blockers 
as the discharge medication.
Statistical Analysis
Continuous variables are presented as means and 
standard deviations or medians and interquar-
tile ranges. Categorical variables are provided 
with percentages. We used the Wilcoxon rank-
sum test to compare continuous variables and 
the Pearson chi-square test or Fisher’s exact test 
to compare categorical variables. For analysis 
of recovery of the left ventricular ejection frac-
tion, one-way analysis of variance was performed. 
Figure 1. Enrollment, Assignment to Substudies, and Follow-Up.
1750 Patients received the diagnosis of takotsubo cardiomyopathy
between 1998 and 2014
Clinical profile 
455 Patients were recruited from the
Zurich Acute Coronary
Syndrome Registry
Analysis of in-hospital
complications
Comparison of 455 patients
from each group matched
for age and sex
468 Had no available information at
30-day follow-up
1282 Were included in 30-day
follow-up analysis
632 Had no available information for
medication-associated survival
analysis
104 Had no information about
medication prescribed at hospital
discharge
72 Died in hospital
456 Had no available information after
discharge
1118 Were included in analysis of survival
associated with medication prescribed
at hospital discharge
1750 Were included in Kaplan–Meier estimates of 30-day and 10-year outcomes
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A two-sided P value of less than 0.05 was con-
sidered to indicate statistical significance.
A chi-square analysis was performed to iden-
tify univariate predictors for in-hospital com-
plications. Variables that were significant in 
univariate analysis were included in a multiple 
logistic-regression analysis to search for inde-
pendent predictors. Model calibration was as-
sessed with the use of the Hosmer–Lemeshow 
test. Odds ratios are reported with 95% confi-
dence intervals.
We used the Kaplan–Meier method to provide 
survival estimates, which were assessed with a 
log-rank test. For survival related to discharge 
medication, two independent propensity scores 
were computed for the use of beta-blockers and 
angiotensin-converting–enzyme inhibitors or 
angiotensin-receptor blockers to limit the influ-
ence of potential confounding variables. For 
computation of the propensity scores, a nonpar-
simonious regression with the medication as a 
dependent variable and potential confounding co-
variates (age, sex, hypertension, diabetes melli-
tus, left ventricular ejection fraction, heart rate, 
use of calcium-channel antagonists, and coro-
nary artery disease) were included. Missing val-
ues were replaced by multiple regression imputa-
tion. We used the Hosmer–Lemeshow test to 
evaluate the validity of logistic regression. One-
year survival after discharge was assessed by 
means of the log-rank test and Cox regression 
with adjustment for the propensity score for 
medication use on a logit scale.
The proportional-hazards assumption was ver-
ified by means of plotting the Schoenfeld residu-
als with Stata software, version 13.1 (StataCorp). 
All analyses were performed with the use of 
SPSS statistical software, versions 21.0 and 22.0 
(IBM). All graphs were compiled with the use of 
Prism 6 software (GraphPad).
R esult s
Study Patients
Of the 1750 patients with takotsubo cardiomy-
opathy, 1571 (89.8%) were women (mean [±SD] 
age, 66.8±13.0 years), and 1384 of all patients 
(79.1%) were women older than 50 years of age 
(Table 1, and Tables S1 and S2 and Fig. S1 in the 
Supplementary Appendix). The predominant symp-
tom on admission was chest pain (75.9%), fol-
lowed by dyspnea (46.9%) and syncope (7.7%). 
Physical triggers were more frequently present 
than emotional triggers (36.0% vs. 27.7%), where-
as 7.8% of patients had both triggers. In 28.5% 
of patients, takotsubo cardiomyopathy occurred 
without any evident trigger. Emotional triggers 
were more common among women, whereas 
physical triggers were more prevalent among 
men (Table 1, and Tables S1 and S2 and Fig. S2 
in the Supplementary Appendix).
Apical takotsubo cardiomyopathy was identi-
fied in 81.7% of patients, whereas the midven-
tricular form was found in 14.6%, and basal and 
focal forms were diagnosed in 2.2% and 1.5%, 
respectively (Fig. 2, Tables S1 and S2 in the Sup-
plementary Appendix, and Videos 1 through 4).
On admission, troponin levels were elevated 
in 87.0% of patients, with mean levels similar to 
those in patients with an acute coronary syn-
drome. Although troponin levels increased by as 
much as a factor of 1.8 during hospitalization 
among patients with takotsubo cardiomyopathy, 
patients with an acute coronary syndrome had 
an increase by a factor of 6 over the admission 
value (P<0.001). Creatine kinase was not sub-
stantially elevated in the majority of patients 
with takotsubo cardiomyopathy (mean level, fac-
tor of 0.87 of the upper limit of the normal 
range). A total of 82.9% of the patients had ele-
vated levels of brain natriuretic peptide on ad-
mission (by a factor of 5.9 of the upper limit of 
the normal range), which significantly exceeded 
the levels among the patients with an acute 
coronary syndrome (Table 1, and Tables S1 and 
S2 in the Supplementary Appendix).
Results on electrocardiography on admission 
showed sinus rhythm in more than 90% of the 
patients with takotsubo cardiomyopathy, who 
had a significantly higher heart rate than patients 
with an acute coronary syndrome. The rates of 
ST-segment elevation were similar in the two 
groups. In contrast, ST-segment depression oc-
curred in only 8.3% of patients with takotsubo 
cardiomyopathy but in 31.1% of those with an 
acute coronary syndrome. Notably, a prolongation 
in the QT interval corrected for heart rate was 
detectable in a substantial proportion of patients 
with takotsubo cardiomyopathy (Table 1, and 
Tables S1 and S2 in the Supplementary Appendix).
A reduced left ventricular ejection fraction 
(mean value, 40.7±11.2%) was noted in 86.5% 
of patients with takotsubo cardiomyopathy on 
admission but in only 54.2% of patients with 
an acute coronary syndrome (mean value, 
51.5±12.3%; P<0.001). Of note, 93.0% of patients 
Videos showing 
left ventricular 
angiography 
are available at 
NEJM.org
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with takotsubo cardiomyopathy had an increased 
left ventricular end-diastolic pressure (>11 mm Hg) 
on angiography (Table 1, and Tables S1 and S2 
and Fig. S3 in the Supplementary Appendix). 
On coronary angiography, coronary artery dis-
ease was diagnosed in 15.3% of patients with 
takotsubo cardiomyopathy. On admission, 32.5% 
of the patients were taking beta-blockers, and 
Characteristic Takotsubo Cardiomyopathy Acute Coronary Syndrome P Value†
Total Cohort 
(N = 1750)
Matched Cohort 
(N = 455)
Matched Cohort 
(N = 455)
Female sex — no. (%) 1571 (89.8) 411 (90.3) 411 (90.3) 1.00
Age — yr 66.4±13.1 67.7±12.5 68.7±12.3 0.19
Chest pain — no./total no. (%) 1229/1619 (75.9) 322/438 (73.5) 361/403 (89.6) <0.001
Dyspnea — no./total no. (%) 760/1620 (46.9) 208/439 (47.4) 128/363 (35.3) 0.001
Median troponin (IQR) — factor × ULN‡ 7.70 (2.22–24.00) 7.68 (2.38–24.21) 8.30 (1.80–36.40) 0.62
Median creatine kinase (IQR) — factor × ULN 0.85 (0.52–1.48) 0.87 (0.55–1.42) 1.12 (0.60–2.97) <0.001
Median brain natriuretic peptide (IQR) — 
factor × ULN§
6.12 (2.12–15.70) 5.89 (1.68–13.92) 2.91 (0.88–8.26) <0.001
ST-segment change — no./total no. (%)
Elevation 690/1578 (43.7) 185/420 (44.0) 233/455 (51.2) 0.03
Depression 121/1578 (7.7) 35/420 (8.3) 122/392 (31.1) <0.001
Heart rate — beats/min 87.5±21.8 87.3±21.8 76.1±18.3 <0.001
Systolic blood pressure — mm Hg 130.6±28.8 131.6±31.4 131.5±28.2 0.96
Left ventricular ejection fraction — %¶ 41.1±11.8 40.7±11.2 51.5±12.3 <0.001
Left ventricular end diastolic pressure — 
mm Hg
21.3±8.0 22.1±7.7 20.1±7.8 0.001
Coexisting medical condition — no./ 
total no. (%)
Coronary artery disease 245/1597 (15.3) 96/455 (21.1) 455/455 (100.0) <0.001
Neurologic or psychiatric disorder‖ 714/1525 (46.8) 252/452 (55.8) 115/448 (25.7) <0.001
Acute neurologic disorder 143/1528 (9.4) 41/452 (9.1) 4/448 (0.9) <0.001
Past or chronic neurologic disorder 293/1512 (19.4) 98/452 (21.7) 62/448 (13.8) 0.002
Acute psychiatric disorder 149/1525 (9.8) 57/452 (1.3) 6/448 (1.3) <0.001
Past or chronic psychiatric disorder 444/1512 (29.4) 165/451 (36.6) 61/448 (13.6) <0.001
Treatment — no./total no. (%)
Catecholamine 212/1735 (12.2) 53/455 (11.6) 50/455 (11.0) 0.75
Invasive or noninvasive ventilation 301/1735 (17.3) 63/455 (13.8) 41/455 (9.0) 0.02
Cardiopulmonary resuscitation 149/1735 (8.6) 40/455 (8.8) 53/455 (11.6) 0.16
In-hospital outcomes — no./total no. (%)
Cardiogenic shock 170/1716 (9.9) 55/445 (12.4) 48/455 (10.5) 0.39
Death 72/1750 (4.1) 17/455 (3.7) 24/455 (5.3) 0.26
*  Plus–minus values are means ±SD. Full details regarding characteristics of patients are provided in Table S2 in the Supplementary Appendix. 
ULN denotes upper limit of the normal range.
†  Means in the matched cohorts were compared with the Wilcoxon rank-sum test, and proportions were compared with the Pearson chi-
square test.
‡  Included in this category are the upper limits of the normal range for troponin T, high-sensitivity troponin T, and troponin I.
§  Included in this category are the upper limits of the normal range for brain natriuretic peptide and the N-terminal of prohormone brain 
 natriuretic peptide.
¶  Data regarding the left ventricular ejection fraction were obtained either during catheterization or echocardiography. If both results were 
available, data that were obtained during catheterization were used.
‖  Patients could have an acute disorder as well as a past or chronic disorder.
Table 1. Characteristics of the Patients at Baseline.*
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37.9% were taking either angiotensin-converting–
enzyme inhibitors or angiotensin-receptor block-
ers, rates of use that increased at discharge (to 
78.1% and 79.3%, respectively) (Table 1, and Ta-
bles S1 and S2 in the Supplementary Appendix).
More than half the patients with takotsubo 
cardiomyopathy (55.8%) had a history or an 
acute episode of a neurologic or psychiatric dis-
order, conditions that were evident in only 25.7% 
of patients with an acute coronary syndrome 
(P<0.001). Specifically, although 27.0% of pa-
tients with takotsubo cardiomyopathy had an 
acute, former, or chronic history of a neurologic 
disorder, 42.3% had received a diagnosis of a 
psychiatric illness, with half of such illnesses 
identified as affective disorders (Fig. S4 in the 
Supplementary Appendix). The high prevalence 
of neurologic and psychiatric disorders was also 
reflected by the fact that a substantial number of 
patients were taking one or more antidepres-
sants (17.1%); most of these medications were 
selective serotonin-reuptake inhibitors or benzo-
diazepines (Table 1, and Table S2 in the Supple-
mentary Appendix).
Clinical Course
Serial echocardiographic assessments of patients 
with takotsubo cardiomyopathy revealed remark-
able recovery of systolic left ventricular function 
over time (Fig. S3 in the Supplementary Appen-
dix). However, 21.8% of patients had a combined 
end point of serious in-hospital complications, 
with rates equal to or higher than those of pa-
tients with an acute coronary syndrome (Table 
S2 and Fig. S5 in the Supplementary Appendix). 
Most of these end points, including in-hospital 
death, occurred more frequently among men 
than among women (Table S1 in the Supple-
mentary Appendix). Furthermore, patients with 
takotsubo cardiomyopathy had some severe 
complications, including ventricular tachycardia 
(3.0%), ventricular thrombus (1.3%), and ven-
tricular rupture (0.2%).
The type of takotsubo cardiomyopathy and 
the coexistence of coronary artery disease were 
not related to the incidence of in-hospital com-
plications, as shown on univariate analysis. 
Multivariate analysis revealed that older age and 
the presence of emotional triggers indepen-
dently predicted a lower incidence of the com-
bined end point. In contrast, the presence of 
physical triggers, acute neurologic or psychiatric 
disease, a first troponin measurement of more 
than 10 times the upper limit of the normal 
level, and a left ventricular ejection fraction of 
less than 45% each predicted a higher incidence 
of the combined end point (Fig. S5 in the Supple-
mentary Appendix).
During the first 30 days after admission, the 
rate of major adverse cardiac and cerebrovascu-
lar events was 7.1%, which included death and 
stroke or transient ischemic attack as the most 
frequent events (Table S1 and Fig. S6 in the 
Supplementary Appendix). Again, men were at 
higher risk for major adverse cardiac and cere-
brovascular events than women (13.7% vs. 6.3%, 
P = 0.002).
Long-Term Outcomes
Long-term follow-up of patients with takotsubo 
cardiomyopathy revealed a rate of death from 
any cause of 5.6% per patient-year and a rate of 
major adverse cardiac and cerebrovascular events 
of 9.9% per patient-year. Among these patients, 
the incidence of myocardial infarction was rela-
tively low, given that the rate of stroke or tran-
sient ischemic attack was 1.7% per patient-year 
and the rate of recurrence of takotsubo cardio-
myopathy was 1.8% per patient-year, with a span 
of 25 days up to 9.2 years after the first event 
(Fig. 3, and Table S1 in the Supplementary Ap-
pendix). Of note, men had increased rates of 
death from any cause (12.9% vs. 5.0% per pa-
tient-year, P<0.001) and major adverse cardiac 
and cerebrovascular events (16.0% vs. 8.7% per 
patient-year, P = 0.002) during long-term follow-
up (Table S1 in the Supplementary Appendix).
In view of the paucity of data regarding ther-
Figure 2 (facing page). Four Types of Takotsubo 
 Cardiomyopathy.
Among the 1750 study patients, the most common type 
of takotsubo (stress) cardiomyopathy was the apical type 
(in 81.7% of patients) (Panels A and B), followed by the 
midventricular type (in 14.6% of patients) (Panels C and 
D), the basal type (in 2.2% of patients) (Panels E and F), 
and the focal type (in 1.5% of patients) (Panels G and H). 
All left ventricular angiograms were obtained in the right 
anterior oblique view (30 degrees) during diastole (left 
column) and systole (middle column). In the far right 
column, the wall-motion abnormality that was observed 
with each type of the disorder is shown, with red indi-
cating diastole, white indicating systole, and the dashed 
line indicating the location of the wall-motion abnor-
mality.
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apy among these patients, we performed a retro-
spective analysis of outcome in relation to the 
medication that had been prescribed at the time 
of hospital discharge, including a propensity-
score analysis to compensate for potential indi-
cation bias. The use of angiotensin-converting–
enzyme inhibitors or angiotensin-receptor blockers 
was associated with improved survival at 1 year 
(P = 0.001 by the log-rank test and after adjust-
ment for the propensity score). In contrast, at 
1 year, there was no evidence of any survival 
benefit for the use of beta-blockers (P = 0.53 by 
the log-rank test; P = 0.72 after adjustment for the 
propensity score) (Table S3 and Fig. S7 in the 
Supplementary Appendix).
Discussion
Our study demonstrates that takotsubo (stress) 
cardiomyopathy represents an acute heart failure 
syndrome that is associated with a substantial 
risk for adverse events. The uneven sex distribu-
tion among the patients with takotsubo cardio-
myopathy that we observed (female-to-male ratio, 
9:1) is in line with most previous reports from 
Western countries.9,16 In Japan, takotsubo cardio-
myopathy is more prevalent among men,17 for 
unclear reasons.
Previous studies have suggested that tako-
tsubo cardiomyopathy is predominantly preced-
ed by emotional triggers.11,18 Subsequent studies 
have indicated that the disease may also occur 
with physical triggers or even without any evident 
preceding trigger.9,19 Our data reveal that the 
prevalence of physical triggers exceeds that of 
emotional triggers and that the absence of a trig-
ger does not preclude a diagnosis of this disorder.
More than half of all patients with takotsubo 
cardiomyopathy had an acute, former, or chronic 
neurologic or psychiatric disorder. This finding 
corroborates and expands findings of previous 
reports involving patients with takotsubo cardio-
myopathy in the context of subarachnoid hemor-
rhage,20 epilepsy,21 electroconvulsive therapy,22 
head injury,23 stroke,24 and anxiety or depres-
sion.25 Of note, the coronary microcirculation is 
innervated by neurons that originate in the brain 
stem and mediate vasoconstriction, which sup-
ports the concept that myocardial stunning due 
to microvascular dysfunction among patients 
with takotsubo cardiomyopathy 26 may be of neu-
rogenic origin.27 Consistently, histopathological 
findings in cardiac tissue samples obtained from 
patients with sudden unexpected death during 
epilepsy or subarachnoid hemorrhage strongly 
resembled those of patients who died during an 
episode of takotsubo cardiomyopathy.5,28 Patients 
with takotsubo cardiomyopathy are more likely 
to present with neurologic and psychiatric disor-
ders than are patients with an acute coronary 
syndrome. This finding suggests a potential link 
between neuropsychiatric disorders and takotsubo 
cardiomyopathy and should prompt prospective 
studies.
Since patients with takotsubo cardiomyopa-
thy commonly present with symptoms similar to 
those among patients with an acute coronary 
syndrome,13 initial diagnosis and treatment of 
patients in the emergency room remains chal-
lenging. Our study confirms that troponin levels 
and electrocardiographic changes on admission 
are not sufficient to differentiate between these 
two disorders,9 since more than 80% of patients 
with takotsubo cardiomyopathy had elevated tro-
ponin levels and nearly 80% had signs of myo-
cardial ischemia on initial electrocardiography. 
Therefore, early coronary angiography remains 
necessary to rule out an acute coronary syndrome. 
Notably, 15.3% of patients with takotsubo car-
diomyopathy had evidence of coexisting coro-
nary artery disease on angiography. This finding 
shows that the presence of coronary artery dis-
ease is not an exclusion criterion for the diagno-
sis of takotsubo cardiomyopathy.13,29
Figure 3. Kaplan–Meier Estimates of 10-Year Outcome Events.
Shown are the proportions of patients with any major adverse cardiac and 
cerebrovascular event (MACCE), which was a composite of death from any 
cause, recurrence of takotsubo cardiomyopathy, stroke or transient ischemic 
attack (TIA), or myocardial infarction (MI).
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Takotsubo cardiomyopathy should be consid-
ered to be an acute heart failure syndrome, as 
reflected by the markedly increased levels of 
brain natriuretic peptide and left ventricular 
end-diastolic pressure. Consistently, systolic left 
ventricular function was reduced to an even 
greater extent among patients with takotsubo 
cardiomyopathy than among those with an acute 
coronary syndrome. In parallel, nearly one fifth 
of all patients with takotsubo cardiomyopathy in 
our study had serious in-hospital complications, 
a proportion that was similar to that of age- and 
sex-matched patients with an acute coronary 
syndrome. This finding illustrates the previously 
underestimated risk of complications during the 
acute phase of the disease and highlights the 
need for concise clinical evaluation, monitoring, 
and management. We identified six measure-
ments for predicting the risk of complications in 
the acute phase. Although elderly patients with 
emotional triggers were at lower risk, younger 
patients with physical triggers and acute neuro-
logic or psychiatric diseases had an increased 
incidence of acute complications. Thus, our data 
show that the spectrum of takotsubo cardiomy-
opathy is wide and ranges from low to very high 
risk in the acute phase. The relatively rapid re-
covery of left ventricular function and a selection 
bias of previous reports toward low-risk patients 
generated the misapprehension that this condi-
tion is a universally benign disease.
Furthermore, patients had substantial rates 
of death and complications after the acute phase 
of the disease, with a rate of death per patient-
year of 5.6% and a rate of stroke or transient 
ischemic attack of 1.7% per patient-year. Thus, it 
is of special interest whether medical treatment 
influences the outcome after the acute phase of 
takotsubo cardiomyopathy. The use of angioten-
sin-converting–enzyme inhibitors or angiotensin-
receptor blockers, but not of beta-blockers, was 
associated with improved survival. Although it 
has been proposed that beta-blockers might pre-
vent takotsubo cardiomyopathy events,12 the con-
dition developed in 32.5% of the patients in our 
study while they were taking these agents. Of 57 
patients with recurrent takotsubo cardiomyopa-
thy, 29 were taking beta-blockers at the time of 
the second event. These data suggest that beta-
blockers are not effective in preventing tako-
tsubo cardiomyopathy. Notwithstanding, these 
findings should be considered solely as hypoth-
esis generating owing to the observational na-
ture of the study.
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